Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc.
Icahn School of Medicine at Mount Sinai
H. Lee Moffitt Cancer Center and Research Institute
University of Wisconsin, Madison
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Assistance Publique - Hôpitaux de Paris